Pathology: mNSCLC - L1 - PDL1 positive;
| mNSCLC - L1 - PDL1 positive | ||||
| MYSTIC (DT ; PDL1>25%), 2020 | CheckMate 227 (NI vs C ; PDL1>1%), 2018 | KEYNOTE-598, 2020 | ||
| durvalumab plus tremelimumab | 1 | T1 | ||
| pembrolizumab plus ipilimumab | 1 | T1 | ||
| nivolumab plus ipilimumab | 1 | T1 | ||
| Standard of Care (SoC) | 0 | T0 | ||
| pembrolizumab plus placebo | 0 | T0 | ||
| pemetrexed plus platin | 0 | T0 | ||